Type 2 papillary renal cell carcinoma (Homo sapiens)

From WikiPathways

Revision as of 23:39, 5 September 2019 by Khanspers (Talk | contribs)
Jump to: navigation, search
2-511MitochondrionNucleusOther genes of interestGene fusionsEpithelial cell of proximal renal tubuleNormoxiaDegradationFHFumarateSETD2EPAS1oxygenTGFb Signaling PathwayVEGF SignalingCitrate CycleTFE3PRCCCDKN1ATFE3SFPQTFE3DVL2CTSKBIRC7DIAPH1HIF1ACTSKTFEBTFEBCOL21A1CADM2HIF1AL-malateEGLN1EGLN2EGLN3HypoxiaPseudohypoxiaELOCELOBVHLRBX1CUL2UbiquitinationARNTARNT2CREBBPEP300SLC2A1VEGFATGFB1TGFB2TGFB3PDGFBTGFAGlucose transportAngiogenesisAutocrine growth stimulationIncreased nutrientsand oxygenCell proliferationLegendActivating mutationInactivating mutation


Description

Based on KEGG

Renal cell carcinoma (RCC), the most common form of kidney cancer in adults, is not a single disease but rather a collection of different tumor types driven by distinct genetic changes that arise within the same tissue. Papillary RCC represents 15 to 20 percent of RCC diagnoses and can manifest as an aggressive, solitary tumor or as multiple, slow-growing tumors. Papillary RCC itself has two main subtypes, type 1 and type 2, that are distinguished histologically. Little is currently known about the genetic basis of non-hereditary papillary RCC and patients receive treatment simply based on disease stage. If caught early, the disease can usually be cured surgically. From https://ccr.cancer.gov/news/article/understanding-papillary-renal-cell-carcinoma

Try the New WikiPathways

View approved pathways at the new wikipathways.org.

Quality Tags

Ontology Terms

 

Bibliography

  1. Linehan WM, Spellman PT, Ricketts CJ, Creighton CJ, Fei SS, Davis C, Wheeler DA, Murray BA, Schmidt L, Vocke CD, Peto M, Al Mamun AA, Shinbrot E, Sethi A, Brooks S, Rathmell WK, Brooks AN, Hoadley KA, Robertson AG, Brooks D, Bowlby R, Sadeghi S, Shen H, Weisenberger DJ, Bootwalla M, Baylin SB, Laird PW, Cherniack AD, Saksena G, Haake S, Li J, Liang H, Lu Y, Mills GB, Akbani R, Leiserson MD, Raphael BJ, Anur P, Bottaro D, Albiges L, Barnabas N, Choueiri TK, Czerniak B, Godwin AK, Hakimi AA, Ho TH, Hsieh J, Ittmann M, Kim WY, Krishnan B, Merino MJ, Mills Shaw KR, Reuter VE, Reznik E, Shelley CS, Shuch B, Signoretti S, Srinivasan R, Tamboli P, Thomas G, Tickoo S, Burnett K, Crain D, Gardner J, Lau K, Mallery D, Morris S, Paulauskis JD, Penny RJ, Shelton C, Shelton WT, Sherman M, Thompson E, Yena P, Avedon MT, Bowen J, Gastier-Foster JM, Gerken M, Leraas KM, Lichtenberg TM, Ramirez NC, Santos T, Wise L, Zmuda E, Demchok JA, Felau I, Hutter CM, Sheth M, Sofia HJ, Tarnuzzer R, Wang Z, Yang L, Zenklusen JC, Zhang J, Ayala B, Baboud J, Chudamani S, Liu J, Lolla L, Naresh R, Pihl T, Sun Q, Wan Y, Wu Y, Ally A, Balasundaram M, Balu S, Beroukhim R, Bodenheimer T, Buhay C, Butterfield YS, Carlsen R, Carter SL, Chao H, Chuah E, Clarke A, Covington KR, Dahdouli M, Dewal N, Dhalla N, Doddapaneni HV, Drummond JA, Gabriel SB, Gibbs RA, Guin R, Hale W, Hawes A, Hayes DN, Holt RA, Hoyle AP, Jefferys SR, Jones SJ, Jones CD, Kalra D, Kovar C, Lewis L, Ma Y, Marra MA, Mayo M, Meng S, Meyerson M, Mieczkowski PA, Moore RA, Morton D, Mose LE, Mungall AJ, Muzny D, Parker JS, Perou CM, Roach J, Schein JE, Schumacher SE, Shi Y, Simons JV, Sipahimalani P, Skelly T, Soloway MG, Sougnez C, Tam A, Tan D, Thiessen N, Veluvolu U, Wang M, Wilkerson MD, Wong T, Wu J, Xi L, Zhou J, Bedford J, Chen F, Fu Y, Gerstein M, Haussler D, Kasaian K, Lai P, Ling S, Radenbaugh A, Van Den Berg D, Weinstein JN, Zhu J, Albert M, Alexopoulou I, Andersen JJ, Auman JT, Bartlett J, Bastacky S, Bergsten J, Blute ML, Boice L, Bollag RJ, Boyd J, Castle E, Chen YB, Cheville JC, Curley E, Davies B, DeVolk A, Dhir R, Dike L, Eckman J, Engel J, Harr J, Hrebinko R, Huang M, Huelsenbeck-Dill L, Iacocca M, Jacobs B, Lobis M, Maranchie JK, McMeekin S, Myers J, Nelson J, Parfitt J, Parwani A, Petrelli N, Rabeno B, Roy S, Salner AL, Slaton J, Stanton M, Thompson RH, Thorne L, Tucker K, Weinberger PM, Winemiller C, Zach LA, Zuna R; ''Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma.''; N Engl J Med, 2016 PubMed Europe PMC Scholia
  2. Sudarshan S, Linehan WM, Neckers L; ''HIF and fumarate hydratase in renal cancer.''; Br J Cancer, 2007 PubMed Europe PMC Scholia
  3. Kauffman EC, Ricketts CJ, Rais-Bahrami S, Yang Y, Merino MJ, Bottaro DP, Srinivasan R, Linehan WM; ''Molecular genetics and cellular features of TFE3 and TFEB fusion kidney cancers.''; Nat Rev Urol, 2014 PubMed Europe PMC Scholia
  4. Medendorp K, van Groningen JJ, Vreede L, Hetterschijt L, Brugmans L, van den Hurk WH, van Kessel AG; ''The renal cell carcinoma-associated oncogenic fusion protein PRCCTFE3 provokes p21 WAF1/CIP1-mediated cell cycle delay.''; Exp Cell Res, 2009 PubMed Europe PMC Scholia
  5. Skalsky YM, Ajuh PM, Parker C, Lamond AI, Goodwin G, Cooper CS; ''PRCC, the commonest TFE3 fusion partner in papillary renal carcinoma is associated with pre-mRNA splicing factors.''; Oncogene, 2001 PubMed Europe PMC Scholia

History

View all...
CompareRevisionActionTimeUserComment
135714view23:52, 29 October 2024EweitzEconomize layout
134152view13:16, 14 July 2024EweitzOntology Term : 'epithelial cell' added !
128737view04:42, 21 February 2024EweitzFix truncated pathway labels, upgrade disease nodes, standardize case
123413view11:13, 25 July 2022EgonwMade three pathways clickable
106520view23:39, 5 September 2019KhanspersModified description
106519view23:38, 5 September 2019KhanspersModified description
97131view19:37, 30 April 2018Khansperstried removing erroneous lit ref
97128view18:30, 30 April 2018KhanspersModified description
97127view18:23, 30 April 2018KhanspersOntology Term : 'papillary renal cell carcinoma' added !
97124view18:11, 30 April 2018Khanspersupdated lit refs, connected interactions
96865view00:50, 15 April 2018AlexanderPicoOntology Term : 'disease pathway' added !
96631view19:31, 23 March 2018KhanspersModified description
96630view19:30, 23 March 2018KhanspersNew pathway

External references

DataNodes

View all...
NameTypeDatabase referenceComment
ARNT2GeneProductENSG00000172379 (Ensembl)
ARNTGeneProductENSG00000143437 (Ensembl)
BIRC7GeneProductENSG00000101197 (Ensembl)
CADM2GeneProductENSG00000175161 (Ensembl)
CDKN1AGeneProductENSG00000124762 (Ensembl)
COL21A1GeneProductENSG00000124749 (Ensembl)
CREBBPGeneProductENSG00000005339 (Ensembl)
CTSKGeneProductENSG00000143387 (Ensembl)
CUL2GeneProductENSG00000108094 (Ensembl)
Citrate CyclePathwayWP78 (WikiPathways)
DIAPH1GeneProductENSG00000131504 (Ensembl)
DVL2GeneProductENSG00000004975 (Ensembl)
EGLN1GeneProductENSG00000135766 (Ensembl)
EGLN2GeneProductENSG00000269858 (Ensembl)
EGLN3GeneProductENSG00000129521 (Ensembl)
ELOBGeneProductENSG00000103363 (Ensembl)
ELOCGeneProductENSG00000154582 (Ensembl)
EP300GeneProductENSG00000100393 (Ensembl)
EPAS1GeneProductENSG00000116016 (Ensembl)
FHGeneProductENSG00000091483 (Ensembl)
FumarateMetaboliteCHEBI:18012 (ChEBI)
HIF1AGeneProductENSG00000100644 (Ensembl)
L-malateMetaboliteCHEBI:15589 (ChEBI)
PDGFBGeneProductENSG00000100311 (Ensembl)
PRCCGeneProductENSG00000143294 (Ensembl)
RBX1GeneProductENSG00000100387 (Ensembl)
SETD2GeneProductENSG00000181555 (Ensembl)
SFPQGeneProductENSG00000116560 (Ensembl)
SLC2A1GeneProductENSG00000117394 (Ensembl)
TFE3GeneProductENSG00000068323 (Ensembl)
TFEBGeneProductENSG00000112561 (Ensembl)
TGFAGeneProductENSG00000163235 (Ensembl)
TGFB1GeneProductENSG00000105329 (Ensembl)
TGFB2GeneProductENSG00000092969 (Ensembl)
TGFB3GeneProductENSG00000119699 (Ensembl)
TGFb Signaling PathwayPathwayWP560 (WikiPathways)
VEGF SignalingPathwayWP3888 (WikiPathways)
VEGFAGeneProductENSG00000112715 (Ensembl)
VHLGeneProductENSG00000134086 (Ensembl)
oxygenMetaboliteCHEBI:25805 (ChEBI)

Annotated Interactions

No annotated interactions

Retrieved from "https://classic.wikipathways.org/index.php/Pathway:WP4241"
Personal tools